Loading stock data…
Alto Neuroscience, Inc. (ANRO)
$35.55-0.85 (-2.34%)
Alto Neuroscience, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ANRO in the Healthcare sector is trading at $35.55 with a market capitalization of $662M. Wall Street consensus targets $38.38 (10 analysts), implying a +8.0% move over the next 12 months. The stock is currently near its 52-week high of $37.48, remaining 59.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +8.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$27.14M↓ | -$17.05M↓ | -$14.95M↑ | -$18.68M↓ | -$15.68M |
| Net Income | -$26.24M↓ | -$16.18M↓ | -$14.18M↑ | -$17.71M↓ | -$15.17M |
Peer Comparison
JNJUNHPFE
Fundamentals
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$661.52M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-30.53%
Volume
Today's trading volume
269,934
Recent News
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?
Alto Neuroscience (ANRO) is back in focus after reporting second quarter 2026 results. The company reported a net loss of US$27.64 million and a basic loss per share from continuing operations of US$0.65. See our latest analysis for Alto Neuroscience. Alto Neuroscience’s latest quarterly loss lands against a backdrop of rapid share price gains, with a 90 day share price return of 47.43% and a year to date share price return of 93.73%, suggesting strong recent momentum. The 1 year total...
Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?
Alto Neuroscience, Inc. reported its second-quarter and first-half 2026 results, recording a wider net loss of US$27.64 million for Q2 and US$53.88 million for the six months ended June 30, 2026, with basic loss per share from continuing operations of US$0.65 and US$1.34, respectively. Despite these larger losses, analysts have maintained a strongly positive stance on Alto Neuroscience, highlighting the progress of its clinical-stage pipeline targeting bipolar depression and major depressive...
Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans
Alto Neuroscience stock has delivered a very large gain over the past year, yet the valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Over the last 12 months, Alto Neuroscience has returned about 9.2x an initial investment, which raises the hurdle for any new buyers who are sensitive to valuation. The expanded development of ALTO-207 and the recent funding that is expected to support operations for several years can help underpin growth...
Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment?
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. Alto Neuroscience, Inc. (NYSE:ANRO) is one of the best up and coming stocks on our list. On June 15, ALTO highlighted the publication in Nature Medicine of Prime-Praxol, an independent randomized, double-blind, placebo-controlled study evaluating pramipexole, a dopamine agonist, […]
Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing
COPT Defense Properties serves defense and intelligence tenants near secure government hubs. Investors will be closely watching whether that niche can keep supporting growth while much of the office market remains under pressure.